Loading clinical trials...
Loading clinical trials...
The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infe...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
BioWest Therapeutics Inc
NCT05870969 · Carcinoma, Hepatocellular, Hepatitis C, Chronic, and more
NCT03200379 · Hepatitis C, Chronic
NCT03155906 · Hepatitis C, Chronic, Opioid Dependence, on Agonist Therapy
NCT03987503 · Hepatitis C, Chronic
NCT05397067 · Hepatitis C, Chronic, Substance Use Disorders
Calgary, Alberta
Edmonton, Alberta
Vancouver, British Columbia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions